Zim Laboratories

Why is Zim Laboratories Ltd falling/rising?

As of 23-Jun, Zim Laboratories Ltd's stock is experiencing a decline of 2.95% after a trend reversal, despite a strong year-to-date performance. Concerns about profitability and negative growth trends have led to investor hesitance, contributing to the stock's current volatility and underperformance compared to its sector.

As of 23-Jun, Zim Laboratories Ltd's stock price is currently falling, with a change of -3.7, representing a decrease of 2.95%. This decline follows a trend reversal after four consecutive days of gains. Although the stock opened with a gain of 2.15% and reached a new 52-week high of Rs 129.3 during the day, it ultimately touched an intraday low of Rs 120, indicating significant volatility.<BR><BR>The stock has underperformed its sector by 4.9% today, which may have contributed to the downward pressure on its price. Additionally, despite a strong year-to-date performance with a 69.29% increase, the company has faced challenges, including a -51.9% decline in profits over the past year. This has raised concerns about its long-term fundamental strength, as evidenced by a -15.97% CAGR growth in operating profits over the last five years and negative results for the last eight consecutive quarters.<BR><BR>Furthermore, the stock is trading at a discount compared to its peers' average historical valuations, which may indicate a lack of confidence among investors. The low level of domestic mutual fund ownership, at 0%, suggests that institutional investors may be hesitant to invest at current price levels, potentially reflecting concerns about the company's profitability and future growth prospects. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Zim Laboratories?

What does Zim Laboratories do?

Zim Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 105 Cr and a net profit of 4 Cr for the quarter ending March 2026. The company has a market cap of INR 610 Cr and key financial metrics include a P/E ratio of 102.00 and a debt-equity ratio of 0.28.

Overview: <BR>Zim Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Zim Laboratories Limited was incorporated in February 1984 as Zim Laboratories Private Limited and later became a Public Limited Company. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 105 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 4 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 610 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 102.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.28 <BR>Return on Equity: 1.98% <BR>Price to Book: 1.96<BR><BR>Contact Details: <BR>Address: Sadoday Gyan (Gr Floor), Opp NADT Nelson Square Nagpur Maharashtra : 440013 <BR>Tel: 91-712-2588070 <BR>Email: md@zimlab.in <BR>Website: http://www.zimlab.in

How big is Zim Laboratories?

As of 10th June, Zim Laboratories Ltd has a market capitalization of 610.00 Cr and reported net sales of 374.40 Cr and a net profit of 5.85 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Zim Laboratories Ltd has a market capitalization of 610.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 374.40 Cr, while the sum of Net Profit for the same period is 5.85 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 296.15 Cr and Total Assets totaling 538.93 Cr.

Who are in the management team of Zim Laboratories?

The management team of Zim Laboratories includes Anwar S Daud (Chairman & Managing Director), Zulfiquar M Kamal (Director of Finance), Prakash Sapkal (Director of Operations), Niraj Dhadiwal (Director of Business Development), and several independent and non-executive directors. This team is responsible for guiding the company's strategic direction and operations.

The management team of Zim Laboratories includes the following members:<BR><BR>1. **Anwar S Daud** - Chairman & Managing Director<BR>2. **Zulfiquar M Kamal** - Director (Finance)<BR>3. **Prakash Sapkal** - Director (Operation)<BR>4. **Niraj Dhadiwal** - Director (Business Development)<BR>5. **Kavita Loya** - Non-Executive & Independent Director<BR>6. **Padmakar Joshi** - Non-Executive & Independent Director<BR>7. **Piyush Nikhadi** - Company Secretary & Compliance Officer<BR>8. **Kamlesh Shende** - Independent Director<BR>9. **Kakasaheb Mahadik** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Zim Laboratories?

Zim Laboratories' peers include Sigachi Industries, Anuh Pharma, Anlon Healthcare, and others. Management risk varies from excellent to below average among peers, with Zim Laboratories showing average growth and a 1-year return of 4.71%.

Peers: The peers of Zim Laboratories are Sigachi Indust., Anuh Pharma, Anlon Healthcare, Shree Ganesh Rem, Kilitch Drugs, Amanta Healthcar, Jenburkt Pharma, Haleos Labs Limi, CCME Global, and Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare and Jenburkt Pharma, while Average management risk is found at Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, Haleos Labs Limi, and Influx Health. Below Average management risk is present at Kilitch Drugs and CCME Global. Growth is Excellent at Anlon Healthcare and Kilitch Drugs, while Average growth is seen at Sigachi Indust., Anuh Pharma, Shree Ganesh Rem, Zim Laboratories, Amanta Healthcar, Jenburkt Pharma, and Haleos Labs Limi. Below Average growth is noted at CCME Global. Capital Structure is Excellent at Sigachi Indust., Anuh Pharma, and Jenburkt Pharma, Good at Anlon Healthcare and Kilitch Drugs, Average at Zim Laboratories, and Below Average at Amanta Healthcar and Haleos Labs Limi.<BR><BR>Return Snapshot: The peer with the highest 1-year return is CCME Global at 348.05%, while the lowest is Sigachi Indust. at -62.71%. Zim Laboratories has a 1-year return of 4.71%, which is higher than Sigachi Indust. but significantly lower than CCME Global. Additionally, Kilitch Drugs, Amanta Healthcar, and Haleos Labs Limi have negative six-month returns.

Are Zim Laboratories Ltd latest results good or bad?

Zim Laboratories Ltd's latest results are concerning, showing a 23.36% decline in net profit and a drop in operating margins to 6.83%, indicating significant operational challenges. Despite a recent stock price increase, the fundamentals suggest weak profitability and sustainability issues.

Zim Laboratories Ltd's latest results indicate a challenging performance. In the fourth quarter of FY26, the company reported a net profit of ₹3.74 crore, which represents a significant decline of 23.36% year-on-year. Revenue also decreased by 3.18% year-on-year, totaling ₹105.27 crore. <BR><BR>One of the most concerning aspects of the results is the sharp drop in operating margins, which fell to 6.83%, down from 13.42% in the same quarter last year. This 659 basis point contraction highlights serious operational challenges and cost management issues. Additionally, the company's return on equity (ROE) is quite low at 2.62%, reflecting weak profitability relative to shareholder funds.<BR><BR>While the stock has shown some short-term momentum, with a 37.91% increase over the past three months, this appears disconnected from the deteriorating fundamentals. The reliance on non-operating income to support profitability raises further concerns about the sustainability of reported profits. Overall, the results suggest that Zim Laboratories is facing significant operational and financial headwinds, making the latest performance more negative than positive.

Should I buy, sell or hold Zim Laboratories Ltd?

When is the next results date for Zim Laboratories Ltd?

The next results date for Zim Laboratories Ltd is 19 May 2026.

The next results date for Zim Laboratories Ltd is scheduled for 19 May 2026.

How has been the historical performance of Zim Laboratories?

Zim Laboratories' historical performance shows fluctuating financial metrics, with net sales at 379.03 Cr in March 2025, a slight increase from the previous year but a decrease from March 2023. Key figures include a rise in operating profit to 49.50 Cr, while profit before tax and profit after tax fell to 18.01 Cr and 12.17 Cr, respectively.

Answer:<BR>The historical performance of Zim Laboratories shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Zim Laboratories reported net sales of 379.03 Cr for the year ending March 2025, a slight increase from 367.42 Cr in March 2024, but a decrease from 398.53 Cr in March 2023. The total operating income followed a similar pattern, reaching 379.03 Cr in March 2025. The raw material costs decreased to 155.00 Cr in March 2025 from 177.70 Cr in March 2024, while employee costs increased to 60.76 Cr from 53.34 Cr. Total expenditure, excluding depreciation, was 335.31 Cr in March 2025, up from 326.09 Cr in March 2024. Operating profit (PBDIT) was 49.50 Cr in March 2025, showing a rise from 46.51 Cr in March 2024, but down from 58.40 Cr in March 2023. Profit before tax decreased to 18.01 Cr in March 2025 from 23.64 Cr in March 2024, and profit after tax also fell to 12.17 Cr from 17.25 Cr. The earnings per share (EPS) dropped to 2.5 in March 2025 from 3.54 in March 2024. On the balance sheet, total assets increased to 472.02 Cr in March 2025 from 446.82 Cr in March 2024, while total liabilities rose to 472.02 Cr from 446.82 Cr. Cash flow from operating activities improved to 41.00 Cr in March 2025 from 16.00 Cr in March 2024, but the net cash outflow was -7.00 Cr in March 2025 compared to a net inflow of 3.00 Cr in March 2024.

Is Zim Laboratories technically bullish or bearish?

As of July 28, 2025, the trend is bullish due to strong daily moving averages and a bullish weekly MACD, despite some mixed signals from the weekly RSI and monthly KST.

As of 28 July 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish, with a strong daily moving average indicating positive momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The MACD is bullish on the weekly chart, supporting the overall bullish outlook, while the monthly MACD remains mildly bullish. Bollinger Bands show a bullish trend on the monthly, reinforcing the positive sentiment. The KST is bullish weekly but bearish monthly, indicating mixed signals. Overall, while there are some conflicting indicators, the prevailing trend is bullish, driven primarily by the daily moving averages and the weekly MACD.

Who are the top shareholders of the Zim Laboratories?

The top shareholders of Zim Laboratories include Anwar Daud with 27.37%, Elizabeth Mathew with 12.02%, and individual investors owning 47.78%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of Zim Laboratories include Anwar Daud, who holds the highest promoter stake at 27.37%. The highest public shareholder is Elizabeth Mathew, with a holding of 12.02%. Additionally, individual investors collectively own 47.78% of the company. There are also two foreign institutional investors (FIIs) that hold a very small percentage, specifically 0.01%. Notably, there are no pledged promoter holdings and no mutual funds involved in the shareholding.

Is Zim Laboratories overvalued or undervalued?

As of March 17, 2025, Zim Laboratories is considered undervalued with a PE ratio of 40.02 and an attractive valuation grade, highlighted by a PEG ratio of 0.00 and a strong recent stock performance of 16.18% over one week, compared to 1.39% for the Sensex.

As of 17 March 2025, Zim Laboratories has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, with a PE ratio of 40.02, an EV to EBITDA of 13.72, and a Price to Book Value of 1.93. These ratios suggest that the stock is trading at a reasonable valuation compared to its earnings and cash flow generation capabilities.<BR><BR>In comparison to its peers, Zim Laboratories stands out with a PEG ratio of 0.00, indicating potential growth at a low price relative to its earnings growth expectations. Notably, the company’s EV to EBITDA ratio is in line with industry standards, while its PE ratio is comparable to other players in the Pharmaceuticals & Biotechnology sector. Recent stock performance has also been strong, with a 1-week return of 16.18% compared to a 1.39% return for the Sensex, reinforcing the attractiveness of the current valuation.

What is the bonus history of the Zim Laboratories?

Zim Laboratories has issued bonuses twice, with a 2:1 bonus on December 22, 2022, and a 1:1 bonus on October 4, 2018, reflecting the company's commitment to rewarding shareholders.

Zim Laboratories has a history of bonus issues that includes two significant events. The most recent bonus was a 2:1 bonus issue, which was announced with an ex-date of December 22, 2022. Prior to that, the company had a 1:1 bonus issue, which took place with an ex-date of October 4, 2018. This indicates that Zim Laboratories has actively engaged in rewarding its shareholders through bonus shares in the past.

Has Zim Laboratories declared dividend?

Zim Laboratories Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 19, 2019. However, the dividend yield is 0%, and total returns over various periods have shown mixed performance, including a significant decline of -55.21% over the last three years.

Zim Laboratories Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 19 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -15.67%, the dividend return was 0%, resulting in a total return of -15.67%.<BR><BR>Over the past year, the price return was -3.57%, with a dividend return of 0%, leading to a total return of -3.57%.<BR><BR>In the 2-year period, the price return was -4.62%, the dividend return was 0%, which resulted in a total return of -4.62%.<BR><BR>For the 3-year period, the price return was -55.21%, with a dividend return of 0%, culminating in a total return of -55.21%.<BR><BR>In the 4-year period, the price return was 14.87%, the dividend return was 0%, resulting in a total return of 14.87%.<BR><BR>Over the last 5 years, the price return was 47.63%, with a dividend return of 0%, leading to a total return of 47.63%.<BR><BR>Overall, while Zim Laboratories declared a dividend, the dividend yield remains at 0%, indicating no recent dividends have contributed to returns. The total returns over various periods show a mix of negative and positive performance, particularly a significant decline over the last three years.